Implication of telomere length as a proliferation-associated marker in schwannomas

Journal of Surgical Oncology

Volumn 81, Issue 2, 2002, Pages 93-100

  Chen, Han Jung ^a,c   Cho, Chung Lung ^b   Liang, Cheng Loong ^a   Lu, Kang ^a   Lin, Jui Wei ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c Chang Gung Medical Foundation   (Taiwan)

Author keywords

Schwannomas; Telomerase; Telomere length

Indexed keywords

DNA; TELOMERASE;

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVOUS SYSTEM TUMOR; NEURILEMOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; SPINAL CORD TUMOR; TELOMERE; TRIGEMINAL NERVE DISEASE; TUMOR DIAGNOSIS;

ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURILEMMOMA; POLYMERASE CHAIN REACTION; TELOMERASE; TELOMERE;

EID: 0036788645     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10139     Document Type: Article

References (33)

1. Samii M, Turel K, Penkert G: Management of seventh and eighth nerve involvement by cerebellopontine angle tumors. Clin Neurosurg 1985;32:242-272.
2. Ducatman BS, Scheithauer BW, Piepgras DG, et al.: Malignant peripheral nerve sheath tumors. A clinico-pathologic study of 120 cases. Cancer 1986;57:2006-2021.
3. Blackburn EH: Structure and function of telomeres. Nature 1991;350:569-573.
4. Zakian VA: Telomerase: Beginning to understand the end. Science 1995;270:1601-1607.
5. Bryan TM, Englezou A, Dalla-Pozza L, et al.: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor derived cell lines. Nat Med 1997;3:1271-1274.
6. Li L, Lejnine S, Makarov V, Langmore JP: In vitro and in vivo reconstitution and stability of vertebrate chromosome ends. Nucleic Acids Res 1998;26:2908-2916.
7. Mondello C, Riboni R, Casati A, et al.: Chromosomal instability and telomere length variations during the life span of human fibroblast clones. Exp Cell Res 1997;236:385-396.
8. Slijepcevic P, Hande MP, Bouffler SD, et al.: Telomere length, chromatin structure and chromosome fusigenic potential. Chromosoma 1997;106:413-421.
9. Allsopp R, Chang E, Kashefi-Aazam M, et al.: Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 1995;200:194-200.
10. Finkel E: Telomeres: Keys to senescence and cancer. Lancet 1998;351:1186.
11. Harley CB, Futcher AB, Greider CW: Telomeres shorten during aging of human fibroblast. Nature 1990;345:458-460.
12. Dahse R, Fiedler W, Ernst G: Telomeres and telomerase: Biological and clinical importance. Clin Chem 1997;43:708-714.
13. Feng J, Funk WD, Wang S, et al.: The RNA component of human telomerase. Science 1995;269:1236-1241.
14. Kim NW: Clinical implication of telomerase in cancer. Eur J Cancer 1997;33:781-786.
15. Kim NW, Piatyszek MA, Prowse KR, et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
16. Kipling D: Telomere structure and telomerase expression during mouse development and tumorigenesis. Eur J Cancer 1997;33: 792-800.
17. Shay JW: Telomerase in human development and cancer. J Cell Physiol 1997;173:266-270.
18. Shay JW, Gazdar AF: Telomerase in the early detection of cancer. J Clin Pathol 1997;50:106-109.
19. Chen HJ, Liang CL, Lu K, et al.: Implication of telomerase activity and alternation of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 2000;89: 2092-2098.
20. Kleihues P, Burger PC, Scheithauer BW (eds): "Histological Typing of Tumors of the Central Nervous System." World Health Organization. Berlin: Springer-Verlag; 1993.
21. Piatyszek MA, Kim NW, Weinrich SL, et al.: Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 1995; 17:1-5.
22. Hastie ND, Dempster M, Dunlop MG, et al.: Telomere reduction in human colorectal carcinoma and with aging. Nature 1990; 346:866-868.
23. Burger PC, Shibata T, Kleiheus P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: Application to surgical neuropathology. Am J Surg Pathol 1989; 10:611-617.
24. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
25. Chong EY, Lam PY, Poon WS, et al.: Telomerase expression in gliomas including the nonastrocytic tumors. Hum Pathol 1998; 29:599-603.
26. DeMasters BK, Markham N, Lillehei KO, et al.: Differential telomerase expression in human primary intracranial tumors. Am J Clin Pathol 1997; 107:548-554.
27. Hiraga S, Ohnishi T, Izumoto S, et al.: Telomerase activity and alternation in telomere length in human brain tumor. Cancer Res 1998;58:2117-2125.
28. Nakatani K, Yoshimi N, Nori H, et al.: The significant role of telomerase activity in human brain tumor. Cancer 1997;80:471-476.
29. Hiyama E, Hiyama K, Yokoyama T, et al.: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-255.
30. Biessmann H, Mason JM: Telomere maintenance without telomerase. Chromosoma 1997;106:63-69.
31. Holt SE, Wright WE, Shay JW: Multiple pathways for the regulation of telomerase activity. Eur J Cancer 1997;33:761-766.
32. Mandal M, Kumar R: Bcl-2 modulates telomerase activity. J Biol Chem 1997;272:14183-14187.
33. Chen HJ, Teng HC, Li SL: Molecular characterization of germline mutations in neurofibromatosis 2 in two families. J Formos Med Assoc 1998;97:869-872.